Designing in Quality: Approaches to Defining the Design Space for a Monoclonal Antibody Process - How to use risk assessment strategies to integrate operations. - BioPharm International


Designing in Quality: Approaches to Defining the Design Space for a Monoclonal Antibody Process
How to use risk assessment strategies to integrate operations.

BioPharm International
Volume 23, Issue 5

Scale-Down Considerations

The applicability of the process understanding obtained from small-scale experiments depends on the validity of the small-scale model.7 Before executing laboratory-scale experiments, a scale-down strategy must be established for all relevant unit operations in the process. As an example, the scale-down strategy for the production bioreactor has been provided, which is one of the most challenging unit operations in terms of establishing a scale-down model.

The strategy encompasses two approaches: one for scale-independent parameters and the other for scale-dependent parameters. For scale-independent parameters, such as temperature, pH, dissolved oxygen, seeding density, and nutrient feed rate, the small-scale model operates at the same set points and uses the same or comparable online or offline control strategies as the commercial-scale bioreactors. This ensures similarity between small-scale and commercial-scale operations. For scale-dependent parameters, such as agitation and gas sparging, scale-up effects should be minimized between the small-scale model and commercial-scale bioreactors. This is achieved through scale-up/scale-down studies that facilitate the determination of appropriate operating conditions.

Figure 4
Of all scale-dependent parameters, four high-risk parameters—agitation, pressure, surface:volume ratio (S:V), and air sparging—were identified through a risk analysis. Their major scale-up effects and the characterization strategy are illustrated in Figure 4. The five major scale-up effects were identified based on process development and scale-up experience. In the multidimensional space, the farther away from the central point, the more pronounced the scale-up effect. For each scale-up effect, an acceptable range was established, within which comparable process performance was observed using corresponding scale-down models. The combined acceptable ranges formed the acceptable space.

Figure 5
When both the commercial-scale and small-scale bioreactors are operated within the same acceptable space, significant scale-up or scale-down effects can be avoided. As a result, the design space established for scale-independent parameters in the laboratory-scale model can be applied to the commercial-scale operation.

Figure 6
As an example, the establishment of the acceptable range for hydrodynamic stress for an NS0 process is summarized below. Two scale-down models were used: a 3-L small-scale bioreactor with a wide range of agitation rates, and a recirculation "torture chamber" model in which cells circulated between a high-shear microfluidic device and a 2-L small-scale bioreactor.8 Both models demonstrated that the NS0 cell line used in the MAb process can withstand an intensive energy dissipation rate (shear) without significant effects on cell growth, productivity (Figures 5 and 6), or product quality (not shown). Though slightly higher in the torture chamber model, cell growth and product titer were within regular batch-to-batch variation.

Establishing the Design Space

An experimental strategy was developed based on several factors, including parameter risk score, operational considerations, and overall process understanding. For example, although chromatography column lifetime may be an important parameter, it is infeasible to study it in a multivariate study along with other parameters because of complexity and cost considerations.

Design of Experiments (DOE) and multivariate analyses were our preferred methods to study parameters with potential interactions, but other approaches, such as one factor at a time (OFAT) and challenge studies, also were used. One DOE study for the production bioreactor focus area is summarized below as an example of the experimental strategy and the definition of the design space.

Seven parameters with potential interactions in the fed-batch production process were studied in one set of DOE studies:

  • seeding cell density
  • cell density at nutrient feed initiation
  • nutrient feed supplementation rate
  • process duration
  • bioreactor temperature
  • bioreactor pH
  • bioreactor dissolved oxygen.

It would have been ideal to study all seven parameters together in a single design, but it was not practical because of resource (bioreactor) limitations. Therefore, we used a two-round DOE approach. The first round was a screening study that included only the first four parameters in the list. The parameters of significant impact were then combined with the remaining three parameters in the second round DOE study.

Figure 7
First Round DOE. A two-level (high and low) full factorial design including center points was used. The study showed that antibody acidic species level was the most sensitive attribute. The two significant parameters that affect the acidic species level were seeding cell density and culture duration, as shown in Figure 7. These two parameters influence acidic species levels cumulatively, without interaction.

Figure 8
Second Round DOE. Seeding cell density and culture duration were incorporated into the second round DOE study with culture pH, temperature, and DO. A central composite design was used to study four of these five parameters. Culture duration was not included in the central composite design. Instead, it was studied by analyzing samples on different days of all batches in the second round DOE study. The second round DOE study revealed again that antibody acidic species level was the most sensitive quality attribute. As indicated in Figure 8 below, three parameters—temperature, seeding density and culture duration—affect acidic species level cumulatively.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here